Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
- Conditions
- HypertensionInsulin ResistanceMicrocirculation
- Interventions
- Registration Number
- NCT00742066
- Lead Sponsor
- Maastricht University Medical Center
- Brief Summary
In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2. Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular effects in normotensive control subjects?
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 32
hypertensive subjects:
- 18-60 years
- Caucasian
- untreated hypertension >140/90mmHg.
normotensive subjects:
- 18-60 years
- Caucasian
- Blood pressure <140/90 mmHg.
- Obesity (BMI>27kg/m2)
- Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)
- Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
- Smoking
- Alcohol use >4U/day
- Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)
- Pregnancy
- Wearing contact lenses
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description I Irbesartan Irbesartan II Felodipine Felodipine III Placebo Placebo
- Primary Outcome Measures
Name Time Method functional recruitment of capillaries in the skin July 2009
- Secondary Outcome Measures
Name Time Method perfused capillary density in the nailfold July 2009 Endothelium- (in)dependent vasodilatation of finger skin microcirculation July 2009 Density of arterioles, capillaries and venules in the bulbar conjunctiva. July 2009 Diameter of arterioles and venules in the bulbar conjunctiva July 2009
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University Hospital Maastricht
🇳🇱Maastricht, P.O. Box 5800, Netherlands
University Hospital Maastricht🇳🇱Maastricht, P.O. Box 5800, Netherlands